The power of patient advocacy in cancer care
Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
Search
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Overcoming stigma and advancing lung cancer advocacy
Lung cancer advocates highlight the need to overcome stigma, access reliable info, and implement early diagnosis and screening.
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Expert insights: the top online lung cancer questions answered
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Small Cell Lung Cancer
Discover more about small cell lung cancer, including its symptoms and treatment options.
Non-small cell lung cancer
Discover more about non-small cell lung cancer, including its symptoms and treatment options.
Larry’s Story: Advocating for people with lung cancer
In 2013, Larry was diagnosed with non-small cell lung cancer. Learn how his diagnosis led him on a journey of patient advocacy for others with cancer.
Targeting HER2 in cancer: The story of zongertinib
We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance
AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
Gastrointestinal Cancers
Gastrointestinal Cancers
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
expanded-collaboration-MD-Anderson
The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
Cancer
Cancer
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Facing lung cancer
Keith and Heather talk about their experiences of facing lung cancer as a family and finding purpose after treatment.
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Living With Cancer
Every cancer journey is unique. Listen to the first-hand experiences of people living with cancer.
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
A life in a day: the reality of living with lung cancer
Within the initiative “A life in a day”, Anna-Maria spent 24 hours in the shoes of a lung cancer patient to better understand the patient experience.
Four Pillars Cancer Immunology
Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation
Dietary Advice for Specific Cancers
Learn more about dietary advice for specific cancers from Taking Cancer On Through Flavour
Cancer's Big 4
We have a robust pipeline of clinical assets including cancer cell-directed therapies, for which we are investigating the key drivers of cancer such as P53 and KRAS.
Big Little Things in cancer: small things, big impacts
Little things can be a big deal when you are living with or treating cancer. Sometimes the small things are the most powerful.